Catalyst Rich 12 Months Ahead for U.S. Biopharma Co.
Source: Scott Henry
August 30, 2023 (Investorideas.com Newswire) Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.
Fortress Biotech Inc. (FBIO:NASDAQ), "significantly undervalued," performed as expected in Q2/23 and has many stock catalysts ahead," reported ROTH Capital Partners analyst Scott Henry in an August 22 research note.
Return Remains Substantial
ROTH lowered its target price on the Florida-based biopharma company to US$2 per share from US$2.25 to "reflect depressed valuations for current public/private assets and a likely near-term reverse stock split." Fortress is currently trading at about US$0.45 per share in comparison.
This difference between these prices implies a significant potential return for investors of 344%.
Fortress is a Buy.
Future Successes Underestimated
As for Fortress being undervalued, Henry explained the company's current market cap of about US$60 million (US$60M) bakes in only two to three future successes despite the biopharma having 20 clinical programs in progress.
"This implies a 10-15% success rate," the analyst added, "which we believe may prove to be 50% or higher."
Key Q2/23 Figures
Henry reported that Fortress generated US$17.4M in revenue during Q2/23, more than ROTH's estimate of US$16.7M. Almost all of the US$17.4M came from Journey Medical, which has "turned momentum positive" in terms of operations and the pipeline. Journey is a company Fortress founded and now owns 50% of.
Fortress' operating expenses in Q2/23 were US$67.5M, below ROTH's forecast of US$69.4M.
The company posted a Q2/23 net earnings per share (EPS) loss of US$0.24, slightly higher than ROTH's predicted EPS loss of US$0.23.
Well-Performing Asset
Henry pointed out how well Journey Medical, which sells and markets drugs for dermatological conditions, is doing.
Coming off of a strong Q2/23, Arizona-based Journey is poised to turn adjusted operations cash flow neutral soon, noted Henry. In H2/23, it plans to file a new drug application (NDA) on DFD-29, its investigative rosacea treatment, supported by strong Phase 3 data. ROTH estimated that peak annual revenue from DFD-20 would exceed US$250M.
"This asset of Fortress appears pointed in the right direction," Henry commented.
What To Watch For
Fortress' pipeline is robust, noted Henry, and numerous stock catalysts are approaching for the biopharma.
Along with the submission of an NDA on DFD-29, events expected to happen this year include the completion of an NDA on CUTX-101, a treatment for Menkes disease. Fortress initiated the application but needs additional information on manufacturing to proceed.
Early next year, on Jan. 3, 2024, is the PDUFA date for cosibelimab for metastatic or locally advanced cutaneous squamous cell carcinoma.
Also, in 2024, potential milestones involving CAEL-101 for AL amyloidosis could occur. The asset is now in Phase 3. Another compound, dotinurad, could move to pivotal trials for gout.
Monetizations on the Horizon
Additional revenue streams could come online in 2024, wrote Henry, specifically from CUTX-101 and CAEL-101. Once CUTX-101 is approved, the sale of a priority voucher, estimated to happen in H2/24, would generate revenue for Fortress in the amount of US$50M-plus.
"Monetizations are key," Henry wrote. "We believe that investors will better appreciate the Fortress business model when monetizations become a more regular occurrence."
More Info:
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
That's all it takes to get an article published on Investor Ideas - Learn More
